Thursday will be the final day of the show. Conference sessions will start at 11am and finish at 2.15 pm – but the trade show exhibition will remain open until 4pm. I hope you have a very successful show and I wish you all safe travels home!
If you’d like something to read on your flight home, why not grab the latest issue of The Medicine Maker? Issues are available for free in Hall 12.1, stand D95. Read an interview with Kite’s Cindy Perettie about GMP manufacturing for cell therapies, and an inspiring story behind an ongoing phase III trial for a TB vaccine, which if approved, would be the world’s first new TB vaccines in 100 years. The issue is also available digitally if you prefer to read on a phone or ipad.
Day 3 agenda highlights (Thursday October 30)
Opening times: 10:00 - 16:00 (for standard pass holders; other pass holders may have earlier access)
11:00 – 11:45: AI’s Impact on the Pharma Workforce and Hiring: From Obsolescence to Opportunity (Hall 6.1, 6.1C92)
The workforce is changing; 90,000 traditional roles are expected to vanish in the future, but new jobs will emerge that demand new skills. This session will explore how AI is reshaping what jobs exist.
11:35 – 12:15: Beyond Traditional Markets: The Strategic Importance of Emerging Pharma Trends and CDMO Innovation (Hall 12.1, 12.1C68)
Interested in CDMO innovation? Then attend this session to find out about current challenges and supply chain impacts, and why collaboration and fostering resilience are key.
11:35 – 12:15: Redrawing the Pharma Investment Map: How Trade and Policy Are Reshaping Capital Flows (Hall 4.1, 4.1L8)
Trade friction and new policies are changing the landscape for pharma manufacturing. Experts look at how capital is flowing from traditional hubs towards regionalized, more politically-aligned ecosystems.
Aprés-Sci
Most of you will no doubt be travelling home after the show but if you are staying longer in the city then there’s a lot to see, including a museum dedicated to golden objects and a peeing tree located in an urban forest. Read more about Frankfurt
Thought of the day
“A lot of SMEs are only looking a month or two ahead. When I work with companies, I spend a lot of time talking about the endgame and asking how they will get their product to market. A lot of companies shrug and say they won’t be the ones doing that. But they still need to understand how their innovation leaves their hands and gets to patients.”
Michael Murray from Murray International Partners. Read more
More from The Medicine Maker
The Economics of Clinical Trials in the Age of AI
A sponsor's perspective on efficiency and scalability gains from using AI.
The Nonprofit Model for Manufacturing
All companies claim to put patients first, but how true is that really when the corporate pharma business revolves around profits?
The Front Lines of Tuberculosis Vaccine Research
There has been no new TB vaccine for over 100 years, but a candidate at the Gates Medical Research Institute in phase III has just finished enrolling the target of 20,000 participants.